“Atypical” Antipsychotics: Finally the Better Choice?

Since the publication of the three so-called „effectiveness“-studies CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness; Lieberman et al., N Engl J Med 2005; 353: 1209–23), CUtLASS (Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia; Jones et al., Arch Gen Psychiatry 2006; 63: 1079–87) and EUFEST (European First Episode Schizophrenia Trial; Kahn et al., Lancet 2008; 371: 1085–97) between 2005 and 2008, which compared the so-called „classical“ or “conventional” (or first-generation antipsychotics, FGA) and the so-called „atypical“ antipsychotics (or second-generation antipsychotics, SGA), the discussion about the question whether the latter provide an advantage in the treatment of patients with schizophrenic disorders became more or less silent. Continue reading